Browse TUSC2

Summary
SymbolTUSC2
Nametumor suppressor candidate 2
Aliases C3orf11; PDAP2; PDGFA associated protein 2; PDGFA-associated protein 2; fus-1 protein; fusion 1 protein
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF15000 Tumour suppressor candidate 2
Function

May function as a tumor suppressor, inhibiting colony formation, causing G1 arrest and ultimately inducing apoptosis in homozygous 3p21.3 120-kb region-deficient cells.

> Gene Ontology
 
Biological Process GO:0001779 natural killer cell differentiation
GO:0001818 negative regulation of cytokine production
GO:0001819 positive regulation of cytokine production
GO:0001906 cell killing
GO:0001909 leukocyte mediated cytotoxicity
GO:0002443 leukocyte mediated immunity
GO:0002444 myeloid leukocyte mediated immunity
GO:0002446 neutrophil mediated immunity
GO:0002521 leukocyte differentiation
GO:0006909 phagocytosis
GO:0021700 developmental maturation
GO:0030098 lymphocyte differentiation
GO:0030101 natural killer cell activation
GO:0031640 killing of cells of other organism
GO:0032602 chemokine production
GO:0032613 interleukin-10 production
GO:0032618 interleukin-15 production
GO:0032620 interleukin-17 production
GO:0032653 regulation of interleukin-10 production
GO:0032660 regulation of interleukin-17 production
GO:0032700 negative regulation of interleukin-17 production
GO:0032733 positive regulation of interleukin-10 production
GO:0035821 modification of morphology or physiology of other organism
GO:0042391 regulation of membrane potential
GO:0042742 defense response to bacterium
GO:0044364 disruption of cells of other organism
GO:0048469 cell maturation
GO:0050829 defense response to Gram-negative bacterium
GO:0051701 interaction with host
GO:0051702 interaction with symbiont
GO:0051817 modification of morphology or physiology of other organism involved in symbiotic interaction
GO:0051818 disruption of cells of other organism involved in symbiotic interaction
GO:0051851 modification by host of symbiont morphology or physiology
GO:0051852 disruption by host of symbiont cells
GO:0051873 killing by host of symbiont cells
GO:0051881 regulation of mitochondrial membrane potential
GO:0051883 killing of cells in other organism involved in symbiotic interaction
GO:0052173 response to defenses of other organism involved in symbiotic interaction
GO:0052200 response to host defenses
GO:0052550 response to defense-related reactive oxygen species production by other organism involved in symbiotic interaction
GO:0052564 response to immune response of other organism involved in symbiotic interaction
GO:0052567 response to defense-related host reactive oxygen species production
GO:0052572 response to host immune response
GO:0070942 neutrophil mediated cytotoxicity
GO:0070943 neutrophil mediated killing of symbiont cell
GO:0070944 neutrophil mediated killing of bacterium
GO:0070945 neutrophil mediated killing of gram-negative bacterium
GO:0071609 chemokine (C-C motif) ligand 5 production
GO:0072593 reactive oxygen species metabolic process
GO:0075136 response to host
GO:0098542 defense response to other organism
GO:2000377 regulation of reactive oxygen species metabolic process
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolTUSC2
Nametumor suppressor candidate 2
Aliases C3orf11; PDAP2; PDGFA associated protein 2; PDGFA-associated protein 2; fus-1 protein; fusion 1 protein
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TUSC2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between TUSC2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29339375Non-Small Cell Lung CarcinomaPromote immunity (T/NK cell function); essential for immunotherapyBecause of the role of TUSC2 in regulating immune cells, we assessed TUSC2 efficacy on antitumor immune responses alone and in combination with anti-PD-1 in two Kras-mutant syngeneic mouse lung cancer models. TUSC2 alone significantly reduced tumor growth and prolonged survival compared with anti-PD-1. When combined, this effect was significantly enhanced, and correlated with a pronounced increases in circulating and splenic natural killer (NK) cells and CD8+ T cells, and a decrease in regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and T-cell checkpoint receptors PD-1, CTLA-4, and TIM-3.
Summary
SymbolTUSC2
Nametumor suppressor candidate 2
Aliases C3orf11; PDAP2; PDGFA associated protein 2; PDGFA-associated protein 2; fus-1 protein; fusion 1 protein
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TUSC2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTUSC2
Nametumor suppressor candidate 2
Aliases C3orf11; PDAP2; PDGFA associated protein 2; PDGFA-associated protein 2; fus-1 protein; fusion 1 protein
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TUSC2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1780.417
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.390.855
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0260.986
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.6430.117
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.5110.713
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.8110.642
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1020.727
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.130.918
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0910.949
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.2260.868
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.4180.838
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.060.378
> Mutation difference between responders and non-responders
 

There is no record.
Summary
SymbolTUSC2
Nametumor suppressor candidate 2
Aliases C3orf11; PDAP2; PDGFA associated protein 2; PDGFA-associated protein 2; fus-1 protein; fusion 1 protein
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TUSC2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTUSC2
Nametumor suppressor candidate 2
Aliases C3orf11; PDAP2; PDGFA associated protein 2; PDGFA-associated protein 2; fus-1 protein; fusion 1 protein
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TUSC2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TUSC2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTUSC2
Nametumor suppressor candidate 2
Aliases C3orf11; PDAP2; PDGFA associated protein 2; PDGFA-associated protein 2; fus-1 protein; fusion 1 protein
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TUSC2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTUSC2
Nametumor suppressor candidate 2
Aliases C3orf11; PDAP2; PDGFA associated protein 2; PDGFA-associated protein 2; fus-1 protein; fusion 1 protein
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TUSC2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTUSC2
Nametumor suppressor candidate 2
Aliases C3orf11; PDAP2; PDGFA associated protein 2; PDGFA-associated protein 2; fus-1 protein; fusion 1 protein
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TUSC2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTUSC2
Nametumor suppressor candidate 2
Aliases C3orf11; PDAP2; PDGFA associated protein 2; PDGFA-associated protein 2; fus-1 protein; fusion 1 protein
Chromosomal Location3p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TUSC2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.